Well there we are. 4.30 at 4.30pm! I just can't wait until tomorrow!! |
A few words today from Frank. |
Indeed. My comment on wealth referred specifically to related investments in the CGT market! With the current rediscovery of socialism as a means of economic (mis) management there will be previous little wealth creation elsewhere! |
Plutonian,
I know you know, but just for everybody else - clinical supply for Arcellx under the Licence and Supply Agreement (LSA) means trial material which will likely be low single digit millions to supply a batch for each trial. Basically a one off for each trial stage at best.
Commercial supply announced back in March (likely for J&J) will be continuous to meet demand when it starts and should be double digit millions yearly once they get established and that will continue for the commercial life of the drug. |
in vivo CAR-T cell engineering. |
CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) demonstrated significantly higher rates of minimal residual disease negativity compared to standard therapies in the phase III CARTITUDE-4 study.
We MAY be contracted to manufacture vector for J&J/Legend which is already approved, but there are safety issues.
Gilead/Arcellx’s Anito-Cel’s Differentiated Safety Profile Challenges J&J/Legend’s Carvykti
We ARE contracted to manufacture vector for Gilead/Arcellx which has just started phase III iMMagine-3 study. |
 Red,
I agree with you about the feelgood side of this, particularly with j-ALL (our original Novartis lead indication) and CF, which both overwhelmingly affect kids.
However, and I realise I'm risking smallcrow holding a rally about this view, your last point there goes hand in hand with the discoveries. If you look at the managed economies then everything is done by committee and although they have very occasionally dropped on something good, mostly the only people who gain are those who sit on the committees and their families.
In the market economies then entrepreneurs see a market opportunity and take a risk which is usually funded by people like us who take part in the funding rounds in hopes of a good return. That system provides many companies chasing the same targets and although most fail it is a system which has delivered us almost everything we take for granted.
In my humble view it's far superior to the state approved hairstyles and the same suits all made in state factories. Unfortunately though there are an increasing number of youngsters around these days who are keen to give that system another try. |
Excellent news commercially: and also, let's all pause and consider, for the people and families who are being given new life because of these technical achievements. There is so much potential for gene therapies emerging now, across a huge range of previously unaddressable conditions, after many years of hard work and vast levels of investment. The next decade will see extraordinary benefits to health. (And, selfishly, to wealth!) |
Just a quick one for this morning:-
We're all familiar with the 20th March RNS
"Recently, the Company signed a contract with a new undisclosed US-based biotechnology company for the manufacture of lentiviral vectors as the client prepares for the commercial launch of its CAR-T programme targeting multiple myeloma. Manufacturing will take place in OxBox, the Company's Oxford-based manufacturing facility.".
As was noted at the time there were only 2 newly approved CAR-T drugs for multiple myeloma with only one of those being "new" to OXB (i.e. not BMS) so the overwhelming probability being the RNS referred to J&J.
J&J news out last night
To get on the trials a patient needs to have been failed by all previous treatments and therefore by default is in a very poorly state. 90% of those evaluable (i.e. stayed in the trial) having undetectable disease this long post-treatment with that statistical power number is an astonishing result.
Almost certainly now it will be rolled out in earlier stage patients who are pre-tested as likely to be refractory to standard treatment and will also by default be much less poorly when they get this (currently last resort) treatment.
MM is one of the more common soft cancers and J&J will sell a lot of this. QED the people who make the programming vector will need to make a lot of that too. |
It will definitely finish at 4.30, LSE rules. |
Got it in one DC :) |
Up this morning (as usual) drop due in an hour or so. Up again this afternoon. Likely finish at ... err... £4.30? |
"stagnated share price this year" - I think looking over the course of the year we are up c.106%, so we have plenty of gains from investors arguably still being sold through holding up more recent progress - but chart still looks strong imvho |
Looks like the story is playing out here - well done to Harry and the gang! I've decided to come back in for a few, to see this, hopefully, to its joyful conclusion. What a way from early in the year when it could be picked up for under £2! |
The 1 share trade periods are littered throughout the stocks recent history, they should be put to one side, they have no relevance. I am interested in the lack of conversation concerning the BR acquisitions in OXB over the course of 2024. In my humble opinion this is hugely significant, and is almost certainly the reason for the stagnated share price this year.
IF BR unshackle OXB's chains sometime next year, then the news will begin to flow and the price will rise accordingly. IF!!!! |
SJ, here is my understanding in jest of how the code works in terms of messaging to fellow market traders:
sell 4 shares - "Can I borrow more stock to sell running low on OXB shares"
sell 3 shares - "Sorry mate we are running low on stock to sell at this price point too"
sell 2 shares = " That's me done then if I cannot borrow stock - all out"
sell 1 share - "We are all out too"
Let's see if my guess was right :) |
I'm more inclined to think those small,1 share,2 share trades etc are some sort of esoteric code between marketmakers but that might be trying to offer an explanation for the inexplicable. |
Not one to grumble but another trade of 1 share just now..we had a load of these trades this week of 1,2,3 or 4 shares - someone trading here must be very bored and prefer this to the crossword puzzles :) |
Not sure what 9374 has to do with anything marwalker |
Which spoke is that ?Directors can't buy for the last six months or more because of a big secret deal or too close to Christmas etc etc |
Adds another spoke to Mr. President's wheel... |
It does feel very like that scenario. |
Yes there appears a cap on the spYou could say that an entity is selling into any strengthAlternatively a cap on the share price would also serve a potential suitor to make their offer more attractiveI remember an ad on US financial channel a bank offering to act on your behalf and keep your strategy under wrapsPays your money etc |
They knocked it down under 4.30 again then. |
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Hot Features
Premium
